Advertisement
Advertisement

Indicator

Free Access

Pay per View

Partial Free Access

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Recurrent Deep Vein Thrombosis and Two Coagulation Factor Gene Mutations: Quo Vadis?

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 1999: 82/6 (Dec) pp.1562-1783
Pages: 1564-1567

Recurrent Deep Vein Thrombosis and Two Coagulation Factor Gene Mutations: Quo Vadis?

Anthonie W. A. Lensing (1) , Martin H. Prins (2)
From the (1) Centre for Vascular Medicine, and the (2) Department of Clinical Epidemiology and Biostatistics, Academic Medical Centre, University of Amsterdam, The Netherlands

Summary

In the past decades considerable progress has been made in the understanding of inherited and acquired causes of venous thrombosis and their clinical impact (1). Thus, the risk of a first venous thrombosis is approximately 10-fold increased in subjects with deficiency of antithrombin, protein C or S (1, 2), 7-fold increased in patients with cancer (3), or the antiphospholipid antibody syndrome (4, 5), and 3 to 5-fold in carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene (6-8). All together, these conditions can be identified in more than 50% of patients with a first episode of venous thrombosis (1, 2, 8).